The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

Faricimab should be readministered with caution in patients who develop mild intraocular inflammation with a previous dose of ...

At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...

Patients with a foveal bulge had significantly enhanced visual acuity if they also had resolved diabetic macular edema (DME) ...

In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for ...

("Ocugen” or the "Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...